Erbitux Tops Roche’s Avastin for Colon Cancer Survival

Merck KGaA’s Erbitux helped patients live longer than Roche Holding AG’s Avastin, a more commonly prescribed treatment, in a head-to-head test of the two drugs in patients with metastatic colon cancer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.